Cloning and characterization of the hamster and guinea pig nicotinic acid receptors April
Smith Torhan,B. Cheewatrakoolpong,L. Kwee,S. Greenfeder
Abstract:In this study, we present the identification and characterization of hamster and guinea pig nicotinic acid receptors. The hamster receptor shares ?80–90% identity with the nucleotide and amino acid sequences of human, mouse, and rat receptors. The guinea pig receptor shares 76–80% identity with the nucleotide and amino acid sequences of these other species. [H]nicotinic acid binding affinity at guinea pig and hamster receptors is similar to that in human (dissociation constant 5 121 nM for guinea pig, 72 nM for hamster, and 74 nM for human), as are potencies of nicotinic acid analogs in competition binding studies. Inhibition of forskolin-stimulated cAMP production by nicotinic acid and related analogs is also similar to the activity in the human receptor. Analysis of mRNA tissue distribution for the hamster and guinea pig nicotinic acid receptors shows expression across a number of tissues, with higher expression in adipose, lung, skeletal muscle, spleen, testis, and ovary.—Smith Torhan, A., B. Cheewatrakoolpong, L. Kwee, and S. Greenfeder. Cloning and characterization of the hamster and guinea pig nicotinic acid receptors. J. Lipid Res. 2007. 48: 2065–2071. Supplementary key words GPR109A & niacin & HM74A Niacin (nicotinic acid) has been used to treat dyslipidemias since the 1950s, when it was discovered that the B-vitamin reduces plasma cholesterol levels (1). In the clinic, niacin has been used to reduce plasma LDL levels, increase HDL, decrease plasma triglycerides, and decrease lipoprotein [a] in patients with or at risk for cardiovascular disease (2–4). The benefits of niacin therapy are limited by poor patient compliance as a result of undesirable side effects. The most common side effect is flushing or cutaneous vasodilation accompanied by a burning sensation, itching, and occasionally hypotension. Pretreatment with aspirin or indomethacin reduces the incidence of flushing for most patients (5, 6). In 2003, several groups reported the identification of a receptor for nicotinic acid, GPR109A (HM74A in humans, PUMA-G in mice) (7–9). GPR109A is a Gia-linked G protein-coupled receptor expressed primarily in adipose and immune cells. GPR109A inhibits cAMP production through the inhibition of adenylate cyclase and exhibits the expected pharmacological profile for a nicotinic acid receptor. Nicotinic acid, Acipimox, and Acifran bind to and activate GPR109A at physiologically relevant concentrations, whereas nicotinamide does not. In mice lacking GPR109A, niacin’s ability to inhibit FFA release is lost (8). Additionally, in recent reports, GPR109A has been shown to mediate the flushing response caused by nicotinic acid in mice and to stimulate prostaglandin production in immune cells (10, 11). This indicates that GPR109A (HM74A/ PUMA-G) is indeed the receptor through which therapeutic doses of niacin act. GPR109A is closely related to two other G proteincoupled receptors that are also expressed in human adipose tissue, GPR109B (HM74) and GPR81 (9). All three genes are located on chromosome 12 in humans, 12q24.31 (9). GPR109B is a low-affinity receptor for nicotinic acid, with activation occurring in the 10–30 mM range. GPR109B is not found in rats or mice, whereas both GPR109A and GPR81 are (7, 9). The endogenous function and ligands for these three related receptors are unknown at present. In this study, orthologs of GPR109A were cloned from the genomic DNA of hamster and guinea pig. The mRNA expression levels in different tissues were examined. The cloned receptors were also characterized by radioligand binding and functionally by measurement of adenylyl cyclase activity. No evidence of a GPR109B homolog in either hamster or guinea pig genomic DNA was found. MATERIALS AND METHODS